Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
about
Rofecoxib for osteoarthritisCOX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patientsCOX-2: where are we in 2003?--distinction from NSAIDs becoming blurredTolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reportsReduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitorsNSAIDs: gastroprotection or selective COX-2 inhibitor?Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis modelThe safety of rofecoxibIncreased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugsPooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillanceDifferences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor.Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.Relationship between cyclooxygenase-2 inhibition and thrombogenesis.Causal Inference for Meta-Analysis and Multi-Level Data Structures, with Application to Randomized Studies of Vioxx.Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now?Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.The classical vs nonclassical NSAIDs: can the reduction in pain overcome the thrombotic risk?Pitfalls in meta-analyses on adverse events reported from clinical trials.COX-2 inhibitors and type 4 error.Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications.Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia.Comparative study of anti-inflammatory and ulcerogenic activities of different cyclo-oxygenase inhibitors.Promoting transparency in pharmaceutical industry-sponsored research.
P2860
Q24244871-402A5CA4-62FF-4F9F-BB00-5587FDEFB1C5Q24796193-ACB85058-B56B-48AC-A297-89512FFC8604Q24804373-39681C32-BDDA-48A7-97D9-7C0681F89B9CQ24816687-8B01F6F9-CF92-4ACA-8F17-74A39B5FA639Q25257303-39C96156-4F2B-4CEC-8C6F-2BA60350AFCBQ28168965-284B0975-0EDF-45EE-8956-99ACEFFD7B56Q28171150-120CEF98-9963-4646-80FB-58342BA1ED37Q28176535-6504213C-95BB-4C90-81F6-6579E3B1F867Q28218432-C5983384-C5DB-4CF5-A909-E40AFC5A886CQ33516504-F747C60B-9009-446D-B868-ED9022391352Q33941101-D52EB4F1-6877-4E6F-8DC5-7A321F20E342Q34464035-F8287771-9101-42C4-9C45-2360466FD971Q35195182-5F2CD064-0A78-4659-8DC8-8E2A4EE8011EQ35750211-9F79C6FD-FC0F-43FC-8358-2C0AD8757178Q36070087-F1F6B015-4EBB-434A-BE22-E8D86B82D618Q36233306-D39AFCF6-9E41-4404-BC55-C8D308C69F50Q36304331-3752EC7E-AE8F-4471-B676-DD46AEC7E711Q36673018-E840B395-E32F-4AC1-BAFE-F216F1A28AC9Q36761358-35A0F1CB-BFF4-4884-9585-A28ED5E51AE9Q36953015-EC5AF459-A2A0-4C5C-880D-A8D1A1C7DC31Q39715445-9FAA368E-BADE-47E1-8F82-B209A2D9FFA2Q42905098-264A717A-F880-4F16-99A0-84BEEBFB3EFAQ44960512-CCD84F00-2C20-4031-BDA7-52489F4258FBQ44975072-ABD841E3-7205-42CB-A518-C5F6392C90E5Q46798434-16AB8029-0C64-4E6E-8B7E-4ACE526D93C4Q53091529-10888348-4EF4-49B5-B4E3-0AE3173A645D
P2860
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Comparison of cardiovascular t ...... , diclofenac, and nabumetone).
@en
Comparison of cardiovascular t ...... , diclofenac, and nabumetone).
@nl
type
label
Comparison of cardiovascular t ...... , diclofenac, and nabumetone).
@en
Comparison of cardiovascular t ...... , diclofenac, and nabumetone).
@nl
prefLabel
Comparison of cardiovascular t ...... , diclofenac, and nabumetone).
@en
Comparison of cardiovascular t ...... , diclofenac, and nabumetone).
@nl
P2093
P921
P1476
Comparison of cardiovascular t ...... , diclofenac, and nabumetone).
@en
P2093
Alise S Reicin
Deborah Shapiro
Eliav Barr
Rhoda S Sperling
P304
P356
10.1016/S0002-9149(01)02201-9
P407
P577
2002-01-01T00:00:00Z